Executive summary of the GESIDA/National AIDS Plan Consensus Document on antiretroviral therapy in adults infected by the human immunodeficiency virus (updated January 2015)
Autores de IIS La Fe
Participantes ajenos a IIS La Fe
- Expert Panel of GESIDA and the National AIDS Plan
- Polo R
- Aguirrebengoa K
- Arribas JR
- Blanco JR
- Boix V
- Casado JL
- Clotet B
- Crespo M
- Estrada V
- García F
- Gatell JM
- González-García J
- Gutiérrez F
- Iribarren JA
- Knobel H
- Llibre JM
- Locutura J
- López JC
- Miró JM
- Moreno S
- Podzamczer D
- Pulido F
- Riera M
- Rubio R
- Santos J
- Sanz-Moreno J
- Téllez MJ
- Tuset M
- Rivero A
Grupos
Abstract
In this update, antiretroviral therapy (ART) is recommended for all patients infected by type 1 human immunodeficiency virus (HIV-1). The strength and grade of the recommendation vary depending on the CD4+ T-lymphocyte count, the presence of opportunistic infections or comorbid conditions, age, and the efforts to prevent the transmission of HIV. The objective of ART is to achieve an undetectable plasma viral load (PVL). Initial ART should comprise three drugs, namely, two nucleoside reverse transcriptase inhibitors (NRTI) and one drug from another family. Three of the recommended regimens, all of which have an integrase strand transfer inhibitor (INSTI) as the third drug, are considered a preferred regimen; a further seven regimens, which are based on an INSTI, an non-nucleoside reverse transcriptase inhibitor (NNRTI), or a protease inhibitor boosted with ritonavir (PI/r), are considered alternatives. The reasons and criteria for switching ART are presented both for patients with an undetectable PVL and for patients who experience virological failure, in which case the rescue regimen should include three (or at least two) drugs that are fully active against HIV. The specific criteria for ART in special situations (acute infection, HIV-2 infection, pregnancy) and comorbid conditions (tuberculosis and other opportunistic infections, kidney disease, liver disease, and cancer) are updated. (C) 2015 Elsevier Espana, S.L.U. and Sociedad Espanola de Enfermedades Infecciosas y Microbiologia Clinics. All rights reserved.
Datos de la publicación
- ISSN/ISSNe:
- 0213-005X, 1578-1852
- Tipo:
- Article
- Páginas:
- 544-556
- PubMed:
- 26021186
- Factor de Impacto:
- 0,378 SCImago ℠
- Cuartil:
- Q3 SCImago ℠
ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA EDICIONES DOYMA S A
Citas Recibidas en Web of Science: 9
Documentos
- No hay documentos
Filiaciones
Filiaciones no disponibles
Keywords
- Antiretroviral treatment; Human immunodeficiency virus infection; AIDS; Guideline; GESIDA; Spanish National AIDS Plan
Cita
Expert Panel of GESIDA and the National AIDS P,BERENGUER J,Polo R,ALDEGUER JL,LOZANO F,Aguirrebengoa K,Arribas JR,Blanco JR,Boix V,Casado JL,Clotet B,Crespo M,DOMINGO P,Estrada V,García F,Gatell JM,González J,Gutiérrez F,Iribarren JA,Knobel H,Llibre JM,Locutura J,López JC,Miró JM,Moreno S,Podzamczer D,PORTILLA J,Pulido F,RIBERA E,Riera M,Rubio R,Santos J,Sanz J,SANZ J,Téllez MJ,Tuset M,Rivero A. Executive summary of the GESIDA/National AIDS Plan Consensus Document on antiretroviral therapy in adults infected by the human immunodeficiency virus (updated January 2015). Enferm. Infec. Microbiol. Clin. 2015. 33. (8):p. 544-556. IF:1,530. (3).
Portal de investigación